BioSpace News Archive

TG Therapeutics, Inc. announced its financial results for the first quarter of 2024, along with recent company developments.

BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.

Neurocrine Biosciences, Inc. announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.

Alkermes plc reported financial results for the first quarter of 2024.

Calidi Biotherapeutics Inc. announced the acceptance of three abstracts that will be presented in a poster session at the 2024 American Society of Clinical Oncology Annual Meeting, taking place from May 31-June 4, 2024, in Chicago, Illinois.

Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024.

ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows.

HiberCell, Inc. is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC).

SIGA Technologies, Inc. announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024.

TFF Pharmaceuticals, Inc announced the closing of its previously announced public offering of an aggregate of 1,665,219 shares of its common stock and warrants to purchase up to 1,665,219 shares of common stock at a combined public offering price of $2.875 per share and accompanying warrant.